A family office with offices in the Northeast and Midwestern United Sates invests its principal capital into high growth companies in both the private and public sectors. The firm’s investment size is highly variable and dependent on the financial needs of the company. The firm often leads investment rounds and also has the ability to leverage its additional network of High-net worth families and like-mined co investors to syndicate for larger deals as well as follow on investments.  The firm looks to invest in companies throughout the United States and has no set number of investments in plans to make, however they are actively reviewing new opportunities.

Within healthcare, the firm is most interested in companies developing Devices and Diagnostics. The firm is looking for companies devices that solve a significant medical problem with strong IP supporting it. The firm is willing to invest in companies from the prototype stage to those that already have their product on the market and is generally agnostic in terms of indication. Historically the firm has invested in companies working with cardiac devices and also has held special interest in the pediatrics space. The firm is generally not as interested in consumer facing devices. The firm is also willing to consider investments in the Therapeutics space though this area is less of a focus.

The firm is looking for companies that have experienced management teams and a strong board behind them. The firm is willing to invest in both privately and public held companies with special interested in making PIPE investments. The firm looks to take a board seat into companies on a case by case basis.

The venture capital arm of a global pharmaceutical with has been established to invest in early stage ideas with breakthrough technologies addressing major unmet medical needs. The firm seeks to make equity investments in Seed and Series A/B rounds. The firm has a global mandate and is currently seeking new investment opportunities.

The firm is currently seeking to invest in early to mid-stage repurposed drugs, repositioned drugs, combination therapies, and new delivery technologies and devices for old drugs. In terms of indications, the firm is focused on oncology, neurology, infectious diseases, and metabolic diseases, but will consider other indications on a case-by-case basis. The firm will prioritize 505(b)(2) opportunities.

The firm seeks companies with a strong and experienced management team. The firm may take a board seat/board observer rights.

A private investment company established by a single high net worth individual is looking to make direct investments in the therapeutics space.  Based in New York City the firm manages an evergreen structure allowing it to have a very large range for investment size, capital structure, and holding period. The firm has no set number of allocations that it plans to make over the next 6-9 months and will evaluate all relevant opportunities on a case by case basis.

The firm is currently looking for US based companies in the therapeutics space and is open to considering both Biologics and Small Molecules. Companies with assets in phase II or later are of high interest, and companies in phase I that have some human efficacy data are also open to consideration. The firm is not interested in therapeutics areas with subjective endpoints such as pain and mental disorders.

The firm is looking for both private and micro-cap publicly held companies and evaluates management on a case by case basis. Taking a board seat is not a requirement for the firm and their involvement in the management of the firm varies based on the needs of the company. The firm is interested in both leading as well as co-investing in investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The strategic venture capital fund of large pharmaceutical company focuses on investments in companies developing pioneering bioelectronic medicines and technologies. The initial investments are typically ranging from $5-$7 million in Series A, and the fund will also consider follow-on investments. The fund is looking to invest in 5 to 7 companies over the next five years. The fund is looking for investment opportunities globally.

The fund is currently looking for new investment opportunities in the Biotech R&D and Medical Technology spaces. The fund focuses on two types of companies, those developing implantable devices targeting neuromodulation of the peripheral nervous system and those developing technologies that improve neuromodulation, such as miniaturized devices, enhanced batteries, etc. The firm is looking for companies generally in the pre-clinical stage of development although companies with in-human data are also open for review.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Private Equity firm based in Western Europe controls €550 million in assets under management across institutional and retail funds. The firm typically makes equity investments ranging from €1 to €20 million over the lifetime of the investment and is also highly interested in the in-licensing of early stage assets and technologies. The firm has an 8 year period to exit and plans to make 2-3 investments over the next 6-9 months. The firm invests in companies located throughout Europe with a focus on France.  For in-licensing opportunities the firm is willing to look globally.

 The firm is currently most interested in companies developing Therapeutics and Medical Devices and is also considering investments in Diagnostics. In the Therapeutics space the firm is open in terms of indication but has strong interest in immunotherapy, vaccines, and biologics subsectors though they are also open to small molecules. In the medical device space the firm has a strong preference for investing in cardiovascular devices but considers other opportunities as well. The firm looks to invest in very early stages of company development generally when lead assets are preclinical and technologies are still in development.

The firm looks to make seed investments as well as being involved in the formulation of a company. The firm is not likely to invest in companies that have already received significant institutional financing and looks to lead investments rounds. The firm also participates in spin-offs from larger companies that are looking to sell non-strategic assets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An international life science investment group based in the eastern US is looking to invest invests in life science companies by using its product development and CRO services effectively as a capital investment. The firm has the ability to leverage 30-70% of the development cost in exchange for equity, downstream royalties, etc. The firm places a strong emphasis in the technology and will invest in companies that are based in the USA, UK, Europe, The Middle East, and Asia. The firm is actively seeking new investment opportunities. 

The firm is currently seeking to invest in biotech therapeutics, diagnostics, and medical devices. For therapeutics, the firm seeks both biologics and small molecule assets that are in pre-clinical through to phase III of clinical trials. For medical devices, the firm is also opportunistic in terms of subsectors and only invests in companies with at least a prototype that is ready for clinic. The firm is open to all indications including orphan indications.

The life science venture investment arm of a leading global Private Equity firm with over $50 billion in AUM, is looking to make investments across development pipeline, from early to late stages. The firm’s investment size is highly variable depending on the stage of the company, ranging from $1M to $50M in equity. The firm has a global mandate and is actively seeking new investment opportunities.

The firm seeks compelling investment opportunities in drug discovery and development platforms developing novel therapeutics, personalized medicine, diagnostics, industrial biotechnology, healthcare services and IT. The firm does not invest in medical devices. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics. 

The firm invests for the long term, and are heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.